Description
Tesamorelin is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH). It consists of a 44-amino acid sequence with a trans-3-hexenoic acid group attached to its N-terminus, a modification that improves its stability compared to naturally occurring GHRH. By stimulating the pituitary gland to release growth hormone, tesamorelin also increases levels of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) in research settings.
Tesamorelin dosage per day
The dose of this medicine will be different for different patients. Follow your doctor’s orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
- For HIV lipodystrophy:
- For injection dosage form 1 milligram (mg) vial:
- Adults—2 mg injected under your skin once a day.
- Children—Use and dose must be determined by your doctor.
- For injection dosage form 2 mg vial:
- Adults—1.4 mg (0.35 milliliters (mL) of the reconstituted solution) injected under your skin once a day.
- Children—Use and dose must be determined by your doctor.
- For injection dosage form 10 mg vial:
- Adults—1.28 mg (0.16 milliliters (mL) of the reconstituted solution) injected under your skin once a day.
- Children—Use and dose must be determined by your doctor.
- For injection dosage form 1 milligram (mg) vial:
Missed Dose
If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Tesamorelin peptide benefits
Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH).
Instead of injecting growth hormone directly, Tesamorelin stimulates your own pituitary to produce growth hormone in a physiologic pattern.
That distinction matters.
- Reduces visceral fat
- Improves waist circumference. Tracking waist size with a tape measure is a practical way to estimate how much visceral fat a person has and monitor changes during peptide therapy.
What Tesamorelin Does:
- Increases endogenous growth hormone
- Reduces visceral adipose tissue (VAT)
- Improves waist circumference
- Supports IGF-1 balance
- May improve liver fat markers
Tesamorelin has been studied extensively in HIV-associated lipodystrophy, where it significantly reduced visceral fat without the same degree of subcutaneous fat loss.
In functional medicine and longevity-focused care, we use it strategically in patients with:
- High visceral fat on imaging or InBody
- Central adiposity resistant to diet and exercise
- Low IGF-1 with metabolic dysfunction
- Early fatty liver patterns
Tesamorelin vs. Sermorelin: Side-by-Side Comparison
| Feature | Tesamorelin | Sermorelin |
|---|---|---|
| Type | Synthetic GHRH analog | GHRH fragment (1–29 amino acids) |
| Mechanism | Direct, potent GH stimulation | Mimics natural GHRH pulses |
| Primary Use | Visceral fat reduction in HIV-associated lipodystrophy | GH deficiency, anti-aging, metabolic health |
| Dosing | Daily subcutaneous injection | Nightly subcutaneous injection |
| Side Effects | Potential for water retention, joint pain, insulin resistance | Mild; generally well tolerated |
| Best For | Clinical fat loss, cognitive enhancement, metabolic correction | Long-term wellness, hormone optimization |
Both Tesamorelin and Sermorelin are effective peptide therapies for stimulating growth hormone production, but their ideal use cases differ:
- Tesamorelin is a clinically validated treatment best suited for targeted fat loss and metabolic correction, especially in populations with HIV-associated lipodystrophy or high visceral fat.
- Sermorelin offers a gentler, long-term solution for those seeking anti-aging, muscle preservation, and natural hormone support with a lower side effect profile.
Tesamorelin vs CJC-1295/Ipamorelin: The Core Clinical Differences
When patients ask about tesamorelin vs cjc-1295 ipamorelin, the comparison comes down to specificity versus breadth. Understanding the tesamorelin benefits alongside the cjc 1295 ipamorelin benefits side by side makes the decision much cleaner. Here is how the two protocols compare on the metrics that matter most:
| Tesamorelin | CJC-1295 / Ipamorelin | |
|---|---|---|
| Primary target | Visceral abdominal fat | Broad GH optimization |
| FDA status | FDA-validated peptide (EGRIFTA SV brand approved for HIV lipodystrophy; compounded version prescribed at Perfect B) | Prescribed via compounding pharmacy |
| GH stimulation pathway | GHRH receptor only | GHRH + ghrelin receptor (dual) |
| Best for | Fat loss, body composition | Recovery, sleep, anti-aging, muscle |
| Injection frequency | Once daily | Once daily |
| Timeline to results | 2 months (2 cycles) | 2 months (2 cycles) |
The core takeaway: tesamorelin is the more precise tool. It does one thing exceptionally well. CJC-1295/Ipamorelin is the broader protocol, with system-wide effects that accumulate over time. Neither is universally superior. The right choice depends entirely on what you are actually trying to achieve.
Can You Combine Tesamorelin and Ipamorelin?
Yes—but with some smart strategy. Tesamorelin and Ipamorelin target different yet complementary aspects of the growth hormone axis. Tesamorelin, as a GHRH analog, pushes the pituitary to produce GH. Ipamorelin, being a GHRP, signals the release of that stored GH. When taken together, they create a synergistic effect that amplifies your body’s natural growth hormone pulse.
This dual-pathway stimulation leads to greater overall GH release than either peptide alone. But timing and dosing matter. You want to avoid flooding your system to the point of diminishing returns. For instance, staggering Tesamorelin in the morning and Ipamorelin in the evening may help avoid saturation and maintain an optimized growth hormone rhythm.
References
- Falutz, J., Mamputu, J., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.. The Journal of clinical endocrinology and metabolism, 95 9, 4291-304 . https://doi.org/10.1210/jc.2010-0490.
- Fourman, L., Billingsley, J., Agyapong, G., Sui, S., Feldpausch, M., Purdy, J., Zheng, I., Pan, C., Corey, K., Torriani, M., Kleiner, D., Hadigan, C., Stanley, T., Chung, R., & Grinspoon, S. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5. https://doi.org/10.1172/jci.insight.140134.
- Lake, J., La, K., Erlandson, K., Adrian, S., Yenokyan, G., Scherzinger, A., Dubé, M., Stanley, T., Grinspoon, S., Falutz, J., Mamputu, J., Marsolais, C., McComsey, G., & Brown, T. (2021). Tesamorelin improves fat quality independent of changes in fat quantity. AIDS, 35, 1395 – 1402. https://doi.org/10.1097/QAD.0000000000002897.
- Grinspoon, S., Fourman, L., Stanley, T., McGary, C., Benkeser, D., & Cash, R. (2025). P-433. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis. Open Forum Infectious Diseases, 12. https://doi.org/10.1093/ofid/ofae631.633.
- Ellis, R., Vaida, F., Hu, K., Dube, M., Henry, B., Chow, F., Heaton, R., Lee, D., & Sattler, F. (2025). Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.. The Journal of infectious diseases. https://doi.org/10.1093/infdis/jiaf012.
